All News
DMARD Treatment Lags for Minority Groups with Rheumatoid Arthritis
Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis of federal survey data indicated, even after adjusting for income, education, and other factors.
Read Article
Changing Loan Limits for Advance Practice Providers
The "One Big Beautiful Bill" (OBBB), or H.R. 1, was signed into law in July, calls for significant changes in the funding of healthcare education. This bill that lowers cap limits on education loans applies to graduate (APRN, PA) programs.
Read Article
High Cost of Cancelling Knee Replacement Surgery
Thousands of NHS knee replacement operations are cancelled at short notice every year, many for avoidable reasons, according to a new study published December 1st. This costs the NHS millions of pounds and increases waiting times for patients, many of whom are in severe pain.
Read Article
Consensus Definitions on Difficult to Treat Psoriatic Arthritis
A substantial number of patients with psoriatic arthritis (PsA), have difficult, persistent and hard-to-treat disease. A GRAPPA task force has developed a consensus terminology for two distinct states: complex-to-manage PsA and treatment-refractory PsA.
Read Article
Turkey Tryptophan (11.28.2025)
Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?
Read Article
Chronic pain may dramatically raise your blood pressure
Widespread chronic pain may stealthily drive up blood pressure, partly through its ties to depression and inflammation.
Read Article
Managing Perioperative DMARDs with Arthroplasty
Postoperative complications with arthroplasty may be related to chronic inflammation and immunosuppressive therapy. Yet a recent retrospective study total ankle arthroplasty in end-stage RA patients shows that early postoperative wound complications are unaffected by the continued use of their preoperative medications including DMARDs.
Read Article
Vitamin D and Lupus Outcomes (11.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
A New Disease Activity Score for Antiphospholipid Syndrome?
APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as thrombotic, microvascular and non-thrombotic (TMN) symptoms.
Read Article
Seeking Musculoskeletal Care
A report entitled The Burden of Musculoskeletal Diseases in the United States (BMUS) report was published by the US Bone and Joint Decade (USBJD) with input from rheumatology, orthopedic surgery, physical medicine and rehabilitation regarding musculoskeletal care.
Read Article
Rheumatology Supply and Demand (2009 - 2024)
A retrospective review of US rheumatology manpower and training between 2009 and 2024 shows that US rheumatology training has become competitive with an increasing surplus of applicants compared to available training positions, which have also increased over time.
Read Article
ACR Applauds Bipartisan Support for Prior Authorization Reform Bill
The American College of Rheumatology (ACR) today commended the more than 295 bipartisan, bicameral cosponsors of The Improving Seniors’ Timely Access to Care Act, which, if enacted, would reform the prior authorization process for Medicare Advantage plans.
Read Article
The Interview (11.7.2025)
I've done thousands of interviews; mostly for medical school admissions or medical and research employment. They’re all the same. I'm looking for the “right one” and the interviewee is somewhere between apprehension, uncertainty and hope. From all this experience I’ve developed my own perspective on interviews and interviewing that has been amended in the digital/virtual era.
Read Article
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA
At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Jiha Lee JihaRheum ( View Tweet)
